Ischemic stroke
Conditions
Interventions
experimental group:Argatroban plus R-tpa
control group:R-tpa
Sponsors
Tianjin First Center Hospita
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years; 2. Time from ocuuring to needle = 6; 5. Consent signed.
Exclusion criteria
Exclusion criteria: 1. Severe neurological deficits prior to onset (mRS >= 2); 2. Significant head trauma or stroke within the last 3 months; 3. Symptoms suggest subarachnoid hemorrhage; 4. With a history of intracranial bleeding; 5. Intracranial tumor, arteriovenous malformation or aneurysm; 6. 3-month intracranial or Crista intramedullary surgery; 7. There's been an arterial puncture in the last 7 days at the non-compressible site; 8. Clotting abnormalities, including a platelet count 1.7, aPTT > 40 s or PT >15 s; 9. AORTIC dissection; 10. Treated with Heparin within 24 hours; 11. Endocarditis; 12. Direct thrombin or factor XA inhibitors are being used; 13. High BP (DP > 185mmHg?OP > 110mmHg); 14. Blood sugar < 50mg/dl (2.7mmol/L); 15. Pregnancy; 16. Residual neurological deficits after seizures; 17. Major surgery or major trauma in the last 30 days; 18. Gastrointestinal or urethral bleeding within the last 30 days; 19. Need anticoagulant therapy outside of the ARGATROBAN; 20. Within 3 months or participating in other clinical trials; 21. Allergic to Argatroban; 22. Other conditions that the researchers considered unsuitable for participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS score; | — |
Countries
China
Contacts
Public ContactZhiyun Wang
Tianjin First Center Hospital
Outcome results
None listed